We served as lead healthcare regulatory counsel, as well as provided antitrust, employee benefits and tax support, for a leading provider of 340B Drug Pricing Program services in its acquisition by a prescription benefit management subsidiary (PBM) of a leading pharmacy healthcare provider.
Pharmacy Benefit Management Acquisition
Client Type: Private Company
You Also May Be Interested In:
-
Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers
-
Representation of Lead Capital Partners, a multi-family sponsored private equity firm, in its acquisition of Ladd Dental Group, Inc., a dental service provider with six locations throughout central Indiana
-
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.